Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Trans Genic Inc. engages in the development, distribution, and licensing of genetically engineered animals and antibodies. It operates through the following segments: Contract Research Organization (CRO), Diagnostic Analysis, and Trans Genic Business Service (TGBS). The CRO segment deals with clinical trials, pharmacological tests, pharmacokinetic tests, non-clinical trials, and the production of genetically modified mice. The Diagnostic Analysis segment provides pathological diagnosis, gene analysis, and drug discovery support services for personalized medicine. The TGBS segment offers advice and support services related to the promotion of new business through mergers and acquisitions, business succession, and business revitalization. The company was founded on April 21, 1998 and is headquartered in Kumamoto, Japan.

Institute For Research In Biomedicine is a Swiss private company located in Bellinzona that provides biomedicine research and development services.\nThe company says this about itself: Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as a1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.

Thyas Co., Ltd. is a company headquartered in Kyoto, Japan, that develops immuno-cell therapy for cancer and infectious diseases. The firm was founded in 2015 by Shin Kaneko. Yasumichi Hitoshi is currently the CEO of the company.

US Agriculture LLC provides investment services. It operates and manage farmland assets and portfolios, develop and implement farmland investment strategies, underwrite and acquire farmland assets across a variety of regions and crop types, develop and implement efficient and effective reporting processes, design and implement investment policies, develop and implement asset allocation strategies, create and implement tools for market and asset targeting, and create and implement portfolio optimization tools and processes. The company was founded in 2015 and is headquartered in Indianapolis, IN.

The Board of Trustees of the University of Illinois, part of University of Illinois, is a company headquartered in Urbana, IL, that trusts Except Educational Religious.

Nanjing Qizhen Genetic Engineering Co., Ltd., established on 2018-05-10, Business scope includes gene technology,Biotechnology,medical technology,Technological Development of Agricultural Technology,technical consulting,technology transfer,Technical Services;Biological Products Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

InfiCure Bio is a life science company, which started as a project at Umeå Biotech Incubator (UBI) in 2013. The project was initiated by Prof. Dan Holmberg and Dr. Sofia Mayans based on research conducted in the research group of Prof. Holmberg at the Universities of Umeå and Lund. The company, InfiCure Bio, was established in 2015 and the founders of the company are Dan Holmberg and Sofia Mayans. he base of the company is a unique preclinical model for studies of fibrosis together with the owners’ competence in the field of inflammation/fibrosis as well as in work with preclinical models. Development of fibrosis in the model is spontaneous, seen in multiple organs (e.g. liver and kidney) and is preceded by chronic inflammation. This resembles many of the human condition that constitute important therapy segments eg chronic liver disease and chronic kidney disease. The company’s preferred business model is to offer pharmaceutical companies to test their new anti-inflammatory/anti-fibrotic drugs in the unique preclinical model. The offer includes set-up, execution, analysis and reporting of results from the effect tests.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Guangzhou Genio Biotechnology Co., Ltd., established on 2010-06-03, Business scope includes commodity wholesale trade(Except for licensed and approved products);Biotechnology Extension Services;Engineering and Technology Research and Experimental Development;Biotechnology Development Services;Sales of products produced by the company(Except for projects prohibited by national laws and regulations;Products involving licensed operation need to obtain a license before they can be operated);Chemical Reagent and Auxiliary Manufacturing(Monitor Chemicals,Excluding hazardous chemicals);Sales of chemical reagents and auxiliaries(Monitor Chemicals,Excluding hazardous chemicals);Sales of biological diagnostic reagents and kits(Does not include license approval items);Research and development of biodiagnostic reagents and kits(Does not include license approval items);

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Recombinetics is a developer of gene editing technologies to improve human health through advanced disease models and regenerative medicine. Its gene-editing technologies manipulate deoxyribonucleic acid (DNA) samples to add and activate genes to solve problems and also offer gene repair and gene editing tools that enable biomedical research, livestock productivity, animal agriculture, and livestock vertical markets to modify animal genomes accurately and efficiently.

Jiangsu Aierkang Biomedical Technology Co., Ltd., established on 2015-10-30, Business scope includes research and development of biochemical products,Production,Sales;Immunology and Molecular Diagnostic Technology,cell therapy technology,biomedicine,Research and Development of Biomaterials,technology transfer,technical consulting;Pharmaceutical Intermediates,Production of test reagents,Sales;one,Production and sales of Class II medical devices;Self-operated and agent import and export of various commodities and technologies(Except for commodities and technologies that the state restricts the company to operate or prohibits the import and export of).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Beijing IDMO Co. Ltd. is a company headquartered in Beijing, China, that engages in research and drug development for relevant animal models. It was founded in 2014 by Si Ying Peng, she has been the CEO since that date.